{"pmid":32345532,"title":"Reply to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.","text":["Reply to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.","Arch Med Res","Das, Undurti N","32345532"],"journal":"Arch Med Res","authors":["Das, Undurti N"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32345532","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.arcmed.2020.04.004","weight":0,"_version_":1665441658278248449,"score":8.599203,"similar":[{"pmid":32327291,"pmcid":"PMC7158796","title":"Bioactive Lipids and Coronavirus (COVID-19).","text":["Bioactive Lipids and Coronavirus (COVID-19).","Arch Med Res","Yasri, Sora","Wiwanitkit, Viroj","32327291"],"journal":"Arch Med Res","authors":["Yasri, Sora","Wiwanitkit, Viroj"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327291","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.arcmed.2020.04.007","e_drugs":["Lipids"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1665420537443123201,"score":120.19373},{"pmid":32229155,"pmcid":"PMC7158796","title":"Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?","text":["Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?","SARS-CoV-2, SARS and MERS are all enveloped viruses that can cause acute respiratory syndrome. Arachidonic acid (AA) and other unsaturated fatty acids (especially eicosapentaenoic acd, EPA and docosahexaenoic acid DHA) are known to inactivate enveloped viruses and inhibit proliferation of various microbial organisms. The pro-inflammatory metabolites of AA and EPA such as prostaglandins, leukotrienes and thromboxanes induce inflammation whereas lipoxins, resolvins, protectins and maresins derived from AA, EPA and DHA not only suppress inflammation but also enhance would healing and augment phagocytosis of macrophages and other immunocytes and decrease microbial load. In view of these actions, it is suggested that AA and other unsaturated fatty acids and their metabolites may serve as endogenous anti-viral compounds and their deficiency may render humans susceptible to SARS-CoV-2, SARS and MERS and other similar viruses' infections. Hence, oral or intravenous administration of AA and other unsaturated fatty acids may aid in enhancing resistance and recovery from SARS-CoV-2, SARS and MERS infections.","Arch Med Res","Das, Undurti N","32229155"],"abstract":["SARS-CoV-2, SARS and MERS are all enveloped viruses that can cause acute respiratory syndrome. Arachidonic acid (AA) and other unsaturated fatty acids (especially eicosapentaenoic acd, EPA and docosahexaenoic acid DHA) are known to inactivate enveloped viruses and inhibit proliferation of various microbial organisms. The pro-inflammatory metabolites of AA and EPA such as prostaglandins, leukotrienes and thromboxanes induce inflammation whereas lipoxins, resolvins, protectins and maresins derived from AA, EPA and DHA not only suppress inflammation but also enhance would healing and augment phagocytosis of macrophages and other immunocytes and decrease microbial load. In view of these actions, it is suggested that AA and other unsaturated fatty acids and their metabolites may serve as endogenous anti-viral compounds and their deficiency may render humans susceptible to SARS-CoV-2, SARS and MERS and other similar viruses' infections. Hence, oral or intravenous administration of AA and other unsaturated fatty acids may aid in enhancing resistance and recovery from SARS-CoV-2, SARS and MERS infections."],"journal":"Arch Med Res","authors":["Das, Undurti N"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32229155","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.arcmed.2020.03.004","keywords":["arachidonic acid","inflammation","lipoxin a4","mers","polyunsaturated fatty acids","prostaglandins","protectins and maresins","resolvins","sars","sars-cov-2"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Fatty Acids, Unsaturated","dehydroacetic acid","Thromboxanes","Lipoxins","Leukotrienes","Prostaglandins","Arachidonic Acid","Docosahexaenoic Acids","Lipids"],"_version_":1664638455324344321,"score":107.02035},{"pmid":32327293,"pmcid":"PMC7158763","title":"Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19.","text":["Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19.","The current outbreak of COVID-19 (coronavirus) has been identified by World Health Organization (WHO) as a global pandemic. With the emergence of the COVID-19 virus and considering the lack of effective pharmaceutical treatment for it, there is an urgent need to identify safe and effective drugs or potential adjuvant therapy in this regard. Bioactive lipids with an array of known health-promoting properties can be suggested as effective agents in alleviating acute respiratory stress induced by virus. The bioactive lipid amide, oleoylethanolamide (OEA), due to several distinctive homeostatic properties, including anti-inflammatory activities, modulation of immune response, and anti-oxidant effects can be considered as a novel potential pharmacological alternative for the management of COVID-19.","Arch Med Res","Ghaffari, Samad","Roshanravan, Neda","Tutunchi, Helda","Ostadrahimi, Alireza","Pouraghaei, Mahboub","Kafil, Behnam","32327293"],"abstract":["The current outbreak of COVID-19 (coronavirus) has been identified by World Health Organization (WHO) as a global pandemic. With the emergence of the COVID-19 virus and considering the lack of effective pharmaceutical treatment for it, there is an urgent need to identify safe and effective drugs or potential adjuvant therapy in this regard. Bioactive lipids with an array of known health-promoting properties can be suggested as effective agents in alleviating acute respiratory stress induced by virus. The bioactive lipid amide, oleoylethanolamide (OEA), due to several distinctive homeostatic properties, including anti-inflammatory activities, modulation of immune response, and anti-oxidant effects can be considered as a novel potential pharmacological alternative for the management of COVID-19."],"journal":"Arch Med Res","authors":["Ghaffari, Samad","Roshanravan, Neda","Tutunchi, Helda","Ostadrahimi, Alireza","Pouraghaei, Mahboub","Kafil, Behnam"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327293","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.arcmed.2020.04.006","keywords":["bioactive lipids","covid-19","coronavirus","oea","oleoylethanolamide"],"e_drugs":["Lipids","oleoylethanolamide","Amides"],"topics":["Treatment"],"weight":1,"_version_":1665420537496600576,"score":91.91014},{"pmid":32277490,"title":"Feto-placental surgeries during the covid-19 pandemic: starting the discussion.","text":["Feto-placental surgeries during the covid-19 pandemic: starting the discussion.","Even though the global COVID-19 pandemic may affect how medical care is delivered in general, most countries try to maintain steady access for women to routine pregnancy care, including fetal anomaly screening. This means that, also during this pandemic, fetal anomalies will be detected, and that discussions regarding invasive genetic testing and possibly fetal therapy will need to take place. For patients, concerns about Severe Acute Respiratory Syndrome-Corona Virus 2 (SARS-CoV2) will add to the anxiety caused by the diagnosis of a serious fetal anomaly, and for fetal medicine teams the situation gets more complex. Yet also for fetal medicine teams the situation gets more complex as they must weigh up the risks and benefits to the fetus as well as the mother, while managing a changing evidence base and logistic challenges in their healthcare system. This article is protected by copyright. All rights reserved.","Prenat Diagn","Deprest, Jan","Van Ranst, Marc","Lannoo, Lore","Bredaki, Emma","Ryan, Greg","David, Anna","Richter, Jute","Van Mieghem, Tim","32277490"],"abstract":["Even though the global COVID-19 pandemic may affect how medical care is delivered in general, most countries try to maintain steady access for women to routine pregnancy care, including fetal anomaly screening. This means that, also during this pandemic, fetal anomalies will be detected, and that discussions regarding invasive genetic testing and possibly fetal therapy will need to take place. For patients, concerns about Severe Acute Respiratory Syndrome-Corona Virus 2 (SARS-CoV2) will add to the anxiety caused by the diagnosis of a serious fetal anomaly, and for fetal medicine teams the situation gets more complex. Yet also for fetal medicine teams the situation gets more complex as they must weigh up the risks and benefits to the fetus as well as the mother, while managing a changing evidence base and logistic challenges in their healthcare system. This article is protected by copyright. All rights reserved."],"journal":"Prenat Diagn","authors":["Deprest, Jan","Van Ranst, Marc","Lannoo, Lore","Bredaki, Emma","Ryan, Greg","David, Anna","Richter, Jute","Van Mieghem, Tim"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277490","week":"202015|Apr 06 - Apr 12","doi":"10.1002/pd.5702","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664636943987638273,"score":47.544857},{"pmid":32074261,"title":"Discussing the ABCs of Health Security-Antibiotic Resistance, Biothreats, and Coronavirus.","text":["Discussing the ABCs of Health Security-Antibiotic Resistance, Biothreats, and Coronavirus.","JAMA","Desai, Angel N","32074261"],"journal":"JAMA","authors":["Desai, Angel N"],"date":"2020-02-20T11:00:00Z","year":2020,"_id":"32074261","week":"20208|Feb 17 - Feb 23","doi":"10.1001/jama.2019.21022","source":"PubMed","topics":["General Info"],"weight":1,"locations":["Biothreats"],"_version_":1664640875249008641,"score":47.393414}]}